A new 3-in-1 asthma drug may provide better and easier control of symptoms for tough-to-treat patients, two new studies suggest.
Trials involved more than 2,500 asthma patients across 17 countries.
Patients tested out an inhaler that contained three drugs: q steroid preventer to control inflammation; a long-acting bronchodilator to keep airways open; and a drug called glycopyrronium to help boost airflow.
The researchers found that putting the three drugs in a single inhaler was more effective in preventing moderate-to-severe asthma attacks than standard therapy with two medicines.
In a news release from a journal, The Lancet, study Co-Author Sandrine Corre said, “Given the reduction, we saw in the annual rate of severe asthma attacks, we expect it will provide an attractive [treatment] option.”
The two trials of the three-drug inhaler were funded by Italian Pharmaceutical Company, Chiesi Farmaceutici, with results published in the journal on Sept. 30. The results were also presented this week at the annual meeting of the European Respiratory Society in Madrid, Spain.
Medical Director at Staten Island University Hospital, in New York City, Theodore Maniatis, explained that simpler is always better when it comes to asthma care.
"The more complicated the inhalational regimen or any regimen, the less likely a patient will comply with the therapy," said Dir. Maniatis, who wasn't involved in the new trials.
Dir. Maniatis added, "Once-a-day therapy is usually fairly easy to handle. "The quest always has been to get as many drugs into an inhalational drug as possible so that the number of treatments or inhalations per day is minimized."
For his part, Dir. Maniatis said the advent of a three-drug asthma inhaler has been a long-sought goal.
"For years, studies have been trying to find the right proportion of these three airway treatments," he explained. "There is a maximum dose of each of these drugs beyond which it does not pay to give more."
However, a pulmonary specialist at Lenox Hill Hospital in New York City, Dr Len Horovitz after reviewing the new findings, stressed that some patients might not be able to "tolerate" all three drugs.
Nevertheless, Dir. Maniatis continued that the encouraging results of the trials could be good news for patients.
"The simpler a medication regimen is, more likely someone is to follow it, and hence the logic behind trying to put these three therapies in one inhalational device," he said.
Latest Stories
-
GNPC new boss Joseph Abuabu Dadzie starts work today
46 mins -
Appiatse disaster: Akufo-Addo to inaugurate 120 housing units
46 mins -
DJ Vyrusky out with new song ‘Follow Who Know Road’
54 mins -
Today’s front pages: Thursday, May 2, 2024
60 mins -
Government steps up efforts to pass new Labour Law
1 hour -
Seven ECG substations in Accra flooded over Wednesday’s downpour
1 hour -
Government to distribute 1.2 million textbooks to TVET schools
1 hour -
TEWU demands government must pay all Tier-2 deductions to fund managers
1 hour -
Cedi hits GH¢14.18 to a dollar; year-to-date loss reaches 13.45%
1 hour -
Akufo-Addo’s assertion of dumsor’s end misleading, says IES
2 hours -
Ghana registers 31 fresh COVID-19 infections
2 hours -
Vote for a government committed to upholding integrity of Public Service – GLOGSAG to Civil Servants
2 hours -
Kasoa protests ‘bad name’
2 hours -
Yaw Nsarkoh: Bit by bit we will understand China
8 hours -
Looted and returned: Asante royal artefacts on display for public viewing at Manhyia Museum
9 hours